|
ANKRD12 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.14300013898117E-10 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
9.312600E-01 |
| Stage1-vs-Stage3 |
3.965600E-02 |
| Stage1-vs-Stage4 |
1.946010E-02 |
| Stage2-vs-Stage3 |
1.533570E-01 |
| Stage2-vs-Stage4 |
6.896100E-02 |
| Stage3-vs-Stage4 |
4.545000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
4.21350000445742E-08 |
| Normal-vs-Asian |
9.85211912052364E-13 |
| Caucasian-vs-AfricanAmerican |
5.266200E-01 |
| Caucasian-vs-Asian |
6.107400E-01 |
| AfricanAmerican-vs-Asian |
8.117800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.33066907387547E-16 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
2.240200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62481139653892E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62492241884138E-12 |
| Normal-vs-Age(81-100Yrs) |
1.581190E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.858590E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.576600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.472600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.233200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.164600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.597800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.616000E-04 |
| Classical-VS-Follicular |
2.810200E-02 |
| Classical-VS-Other |
3.172800E-01 |
| Classical-VS-Normal |
1.65523150741365E-12 |
| Tall-VS-Follicular |
1.56865999999534E-05 |
| Tall-VS-Other |
6.343800E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
1.283410E-01 |
| Follicular-VS-Normal |
1.03320019206876E-10 |
| Other-VS-Normal |
2.48769999999787E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
3.99680288865056E-15 |
| N0-vs-N1 |
2.401800E-01 |
|
|
